Cardiff Oncology, Inc.
CRDF· Nasdaq
CRDFCardiff Oncology, Inc.
Filed Feb 27, 2020 · 10-K · 58 days after period end · 0001628280-20-002424
derived · Computed from the longer spans the company filed.
| Metric | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures | Q4 2017 | Q4 2016 |
|---|---|---|---|---|
| Revenue | $94.07K | $78.02K | $185.00K | $68.00K |
| Net Income | -$4.24M | -$4.16M | -$2.57M | -$8.55M |
| EPS Diluted | — | — | -$0.06 | -$0.34 |
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2019 · filed Feb 27, 2020 · 58 d after period end
